Vera Therapeutics (VERA) Payables (2020 - 2026)
Vera Therapeutics' (VERA) quarterly Payables came in at $13.9 million in Q1 2026, up 50.17% YoY from $9.3 million in Q1 2025, and down 36.48% on a QoQ basis from $21.9 million in Q4 2025.
Vera Therapeutics (VERA) Payables (2020 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 7 years of Payables data on file, last reported at $13.9 million in Q1 2026.
- Quarterly Payables rose 50.17% year-over-year to $13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (up 50.17% YoY) and the FY2025 annual result came in at $21.9 million, up 185.69% from the prior year.
- Payables fell to $13.9 million in Q1 2026, from $21.9 million in the prior quarter.
- In the past five years, Payables ranged from a high of $21.9 million in Q4 2025 to a low of $4.6 million in Q3 2024.
- A 5-year average of $10.2 million and a median of $9.3 million in 2025 frame the typical range for Payables.
- Annual changes were most pronounced in 2022 — Payables soared 765.78% — and 2024, when it slumped 64.88%.
- Tracing VERA's Payables over 5 years: stood at $12.0 million in 2022, then slipped by 7.28% to $11.1 million in 2023, then sank by 31.06% to $7.7 million in 2024, then jumped by 185.69% to $21.9 million in 2025, then plunged by 36.48% to $13.9 million in 2026.
- The last three Payables figures came in at $13.9 million (Q1 2026), $21.9 million (Q4 2025), and $18.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Vera Therapeutics | 2.28 Bn | 2.28 Bn | - | 14.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.57 Mn |
| Mar 31, 2026 | 13.91 Mn |
| Dec 31, 2025 | 21.90 Mn |
| Sep 30, 2025 | 17.95 Mn |
| Jun 30, 2025 | 13.16 Mn |
| Mar 31, 2025 | 9.26 Mn |
| Dec 31, 2024 | 7.67 Mn |
| Sep 30, 2024 | 4.60 Mn |
| Jun 30, 2024 | 4.66 Mn |
| Mar 31, 2024 | 5.21 Mn |
| Dec 31, 2023 | 11.12 Mn |
| Sep 30, 2023 | 12.30 Mn |
| Jun 30, 2023 | 13.28 Mn |
| Mar 31, 2023 | 5.33 Mn |
| Dec 31, 2022 | 11.99 Mn |
| Sep 30, 2022 | 7.01 Mn |
| Jun 30, 2022 | 7.08 Mn |
| Mar 31, 2022 | 7.33 Mn |
| Dec 31, 2021 | 1.39 Mn |
| Sep 30, 2021 | 964,000.00 |